Clinical Trial Update: Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Anlotinib for second-line therapy in elderly patients with EGFR wild-type lung adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)

Snippet

Sponsor: First Affiliated Hospital of Wenzhou Medical University | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: UNKNOWN